Rewalk Robotics Ltd. ( (LFWD) ) has released its Q3 earnings. Here is a breakdown of the information Rewalk Robotics Ltd. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lifeward Ltd., a global leader in medical technology, focuses on developing innovative solutions for individuals with physical limitations or disabilities, offering products like the ReWalk Exoskeleton and AlterG Anti-Gravity system.
In its third-quarter 2025 financial report, Lifeward Ltd. highlighted a record number of ReWalk systems placements for Medicare beneficiaries, a significant reduction in cash burn, and a new $3.0 million loan agreement to bolster capital support.
Key financial metrics revealed a slight revenue increase to $6.2 million, driven by Medicare-related sales, while operational efficiencies led to a 16% decrease in cash burn and a 27% reduction in non-GAAP operating loss. The company also secured CE mark approval for its ReWalk 7 Personal Exoskeleton, facilitating European sales.
Despite a net loss of $3.2 million, Lifeward’s strategic focus on operational efficiency and market expansion positions it for future growth. The company remains optimistic about its transformation efforts and expects continued momentum in the coming quarters.